TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 6105907

Group type: EXPERIMENTAL
Intervention: Flunitrazepam 0.05 mg . kg‐1
Number of subjects: 40

Group type: COMPARATOR
Intervention: Thiopentone 6.0 mg . kg‐1
Number of subjects: 40
Study: 30950685

Group type: EXPERIMENTAL
Intervention: Short response time deadlines (400 ms)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Middle response time deadlines (700 ms)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Long response time deadlines (1,000 ms)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Low-context sentences
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: High-context sentences
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 4-alternative forced-choice response
Number of subjects: 30
Study: 28045137

Group type: EXPERIMENTAL
Intervention: L. plantarum TIFN101
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: L. plantarum WCFS1
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: L. plantarum CIP104448
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Indomethacin (artificial stressor)
Number of subjects: 10
Study: 26349025

Group type: EXPERIMENTAL
Intervention: Feedback device
Number of subjects: 36

Group type: COMPARATOR
Intervention: No feedback device
Number of subjects: 36
Study: 23953270

Group type: EXPERIMENTAL
Intervention: quetiapine XR (400-800 mg)
Number of subjects: 798

Group type: COMPARATOR
Intervention: risperidone (2-6 mg)
Number of subjects: 798
Study: 21298628

Group type: EXPERIMENTAL
Intervention: Tears Again®
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Optive®
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Opticol®
Number of subjects: 27

Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 27
Study: 19639375

Group type: EXPERIMENTAL
Intervention: Propofol infusion rate of 50 microg x kg(‐1) x min(‐1)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Propofol infusion rate of 100 microg x kg(‐1) x min(‐1)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Propofol infusion rate of 150 microg x kg(‐1) x min(‐1)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Propofol infusion rate of 120 microg x kg(‐1) x min(‐1)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Predicted infusion rate to achieve a mean concentration of 5 microg x mL(‐1)
Number of subjects: 24
Study: 16798042

Group type: EXPERIMENTAL
Intervention: Doxycycline-rifampin-amikacin (ADR) regimen: doxycycline 100 mg twice a day, rifampin 10 mg/kg body weight/day every morning for eight weeks, plus 7.5 mg/kg amikacin intramuscularly twice a day for seven days.
Number of subjects: 220

Group type: COMPARATOR
Intervention: Doxycycline-rifampin (DR) regimen: doxycycline 100 mg twice a day and rifampin 10 mg/kg body weight/day every morning for eight weeks.
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Doxycycline-rifampin-amikacin (ADR) regimen
Number of subjects: 220

Group type: COMPARATOR
Intervention: Doxycycline-rifampin (DR) regimen
Number of subjects: 220
Study: 15385902

Group type: EXPERIMENTAL
Intervention: In-person intervention (3-module intervention totaling 18 sessions)
Number of subjects: 175

Group type: COMPARATOR
Intervention: Delayed-intervention condition
Number of subjects: 175
Study: 11896119

Group type: EXPERIMENTAL
Intervention: Bolus doxorubicin (30 mg/m2 every 3 weeks for a total of 360 mg/m2)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Continuous infusion of doxorubicin (360 mg/m2 over 48 hours)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Both groups (Bolus and Continuous infusion)
Number of subjects: 121
Study: 10208077

Group type: EXPERIMENTAL
Intervention: Ca‐P‐MFP‐urea test rinse
Number of subjects: 5

Group type: COMPARATOR
Intervention: NaCl placebo rinse
Number of subjects: 5
Study: 7885261

Group type: EXPERIMENTAL
Intervention: Intermediate difficulty narrative texts
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intermediate difficulty expository texts
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Text difficulty (nonmonotonic function)
Number of subjects: 0
Study: 2239812

Group type: EXPERIMENTAL
Intervention: Aconiti Tuber (prepared at 120 degrees C for 40 min)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 901996

Group type: EXPERIMENTAL
Intervention: Acebutolol
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 11
Study: 31044235

Group type: EXPERIMENTAL
Intervention: 8 mg moxidectin
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: 16 mg moxidectin
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: 24 mg moxidectin
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: 8 mg moxidectin plus 400 mg albendazole
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: 16 mg moxidectin plus 400 mg albendazole
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: 24 mg moxidectin plus 400 mg albendazole
Number of subjects: 290

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 290
Study: 30834991

Group type: EXPERIMENTAL
Intervention: WaveOne Gold (WOG)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: XP‐endo Shaper (XPS)
Number of subjects: 0
Study: 28199814

Group type: EXPERIMENTAL
Intervention: Baricitinib 4 mg once daily
Number of subjects: 1307

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1307

Group type: COMPARATOR
Intervention: Adalimumab 40 mg every other week
Number of subjects: 1307
Study: 26320479

Group type: COMPARATOR
Intervention: Cisplatin 15mg/m2
Number of subjects: 180

Group type: COMPARATOR
Intervention: Cisplatin 20mg/m2
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Lobaplatin 35mg/m2
Number of subjects: 180
Study: 22609723

Group type: EXPERIMENTAL
Intervention: Pentax‐Airwayscope (AWS)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Macintosh laryngoscope (McL)
Number of subjects: 36
Study: 24149557

Group type: EXPERIMENTAL
Intervention: Dance exercise (twice a week for 6 months)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group (no dance exercise)
Number of subjects: 38
Study: 19349290

Group type: EXPERIMENTAL
Intervention: Broccoli sprouts (70 g/d; containing 420 micromol of SF precursor) for 8 weeks
Number of subjects: 48

Group type: COMPARATOR
Intervention: Alfalfa sprouts (placebo) for 8 weeks
Number of subjects: 48
Study: 16785289

Group type: EXPERIMENTAL
Intervention: Short-term umbilical vein catheter (7-10 days) followed by percutaneous central venous catheter
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Long-term umbilical vein catheter (up to 28 days)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Short-term umbilical vein catheter
Number of subjects: 210

Group type: COMPARATOR
Intervention: Long-term umbilical vein catheter
Number of subjects: 210

Group type: COMPARATOR
Intervention: Small-for-gestational-age infants (9 out of 45 developed thrombi)
Number of subjects: 210
Study: 15204158

Group type: EXPERIMENTAL
Intervention: Acitretin 25-50 mg/day for 1 month
Number of subjects: 42

Group type: COMPARATOR
Intervention: Conventional topical treatment (betamethasone/salicylic acid ointment)
Number of subjects: 42
Study: 11967517

Group type: EXPERIMENTAL
Intervention: Intensive laboratory-based laparoscopic skills training curriculum
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (no formal practice sessions)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Both groups (skills and control)
Number of subjects: 26
Study: 9839766

Group type: EXPERIMENTAL
Intervention: Donepezil HCl (10 mg day(-1)) administered for 19 consecutive days with a single dose of warfarin (25 mg) on day 14.
Number of subjects: 12

Group type: COMPARATOR
Intervention: Warfarin (25 mg) administered alone on day 14 after an initial 13-day period with no medication.
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Donepezil HCl (10 mg day(-1)) administered for 19 days with an additional single dose of warfarin (25 mg) on day 41 after a washout period.
Number of subjects: 12
Study: 7648286

Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT) with 2 mg Photofrin/kg and 120 J/cm2 laser light (n = 5)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT) with 2 mg Photofrin/kg and 70 J/cm2 laser light (n = 4)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT) with 2 mg Photofrin/kg
Number of subjects: 8
Study: 2664886

Group type: EXPERIMENTAL
Intervention: Tetrabamate
Number of subjects: 60

Group type: COMPARATOR
Intervention: Chlordiazepoxide
Number of subjects: 60
Study: 70947

Group type: EXPERIMENTAL
Intervention: Oxatimide (20 mg, two tablets three times a day for 2 weeks)
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: Diphenhydramine consumption
Number of subjects: 215
Study: 30444690

Group type: EXPERIMENTAL
Intervention: Bulk-fill resin composite (Filtek Bulk-Fill Posterior Restorative)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Composite CAD/CAM inlays (Lava Ultimate)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control group (intact teeth)
Number of subjects: 51
Study: 29538697

Group type: EXPERIMENTAL
Intervention: Risk stratification tool for invasive melanoma
Number of subjects: 41954

Group type: EXPERIMENTAL
Intervention: Risk stratification tool for all melanomas (invasive + in situ)
Number of subjects: 41954
Study: 26190853

Group type: EXPERIMENTAL
Intervention: Four positions for intratracheal beractant administration (Group I)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Two positions for intratracheal beractant administration (Group II)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Neutral position for intratracheal beractant administration (Group III)
Number of subjects: 125
Study: 24463668

Group type: EXPERIMENTAL
Intervention: Phone follow-up with semiquantitative urine pregnancy test and symptom checklist
Number of subjects: 1433

Group type: EXPERIMENTAL
Intervention: Phone follow-up with semiquantitative urine pregnancy test
Number of subjects: 1433

Group type: EXPERIMENTAL
Intervention: Semiquantitative pregnancy test alone (without symptom checklist)
Number of subjects: 1433

Group type: COMPARATOR
Intervention: Clinic follow-up
Number of subjects: 1433
Study: 22357901

Group type: EXPERIMENTAL
Intervention: 20 mg of controlled-release oxycodone (CRO)
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: 10 mg of controlled-release oxycodone (CRO)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 210
Study: 20075530

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine infusion (1 microg/kg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 30
Study: 17601720

Group type: EXPERIMENTAL
Intervention: Heated humidification during nasal NIV
Number of subjects: 16

Group type: COMPARATOR
Intervention: Without heated humidification during nasal NIV
Number of subjects: 16
Study: 15704510

Group type: EXPERIMENTAL
Intervention: Modified Ashworth Scale (MAS) assessment with different stretching velocities
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Presence of contractures
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Stretching velocity
Number of subjects: 50
Study: 12490344

Group type: EXPERIMENTAL
Intervention: Topiramate (300-400 mg/day)
Number of subjects: 35
Study: 10363537

Group type: EXPERIMENTAL
Intervention: Progressive relaxation exercise (experimental group)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Control group (no relaxation therapy)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Nonadherent group (did not practice relaxation)
Number of subjects: 107
Study: 8784215

Group type: EXPERIMENTAL
Intervention: Felbamate (FBM)
Number of subjects: 0
Study: 2144018

Group type: EXPERIMENTAL
Intervention: Continuous infusion floxuridine (FUDR) at 0.15 mg/kg/d (IV) or 0.25 mg/kg/d (IA) for 14 days at monthly intervals.
Number of subjects: 68
Study: 7316249

Group type: EXPERIMENTAL
Intervention: Environmental Control Unit (ECU) treatment, where patients were taken off all medication and not fed until leg pain and swelling disappeared (4 to 7 days).
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Environmental Control Unit (ECU) treatment with daily exercycle at 150 kpm for one mile to demonstrate absence of phlebitis.
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard anticoagulant regime, bed rest, and support hose (control group).
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Environmental Control Unit (ECU) treatment.
Number of subjects: 20
Study: 31230466

Group type: EXPERIMENTAL
Intervention: Pilates method intervention (24 sessions over 12 weeks)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Standard clinical treatment (control group)
Number of subjects: 51
Study: 27616331

Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.75% plus dexmedetomidine 1mg/kg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ropivacaine 0.75% plus clonidine 1mg/kg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ropivacaine 0.75%
Number of subjects: 0
Study: 26453532

Group type: EXPERIMENTAL
Intervention: Healing Touch (HT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional Nursing Care (TNC)
Number of subjects: 0
Study: 25128296

Group type: EXPERIMENTAL
Intervention: Healthy Nordic diet (ND)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Habitual Western diet (Control)
Number of subjects: 88
Study: 21905981

Group type: EXPERIMENTAL
Intervention: Radical prostatectomy (RP)
Number of subjects: 0
Study: 19183128

Group type: EXPERIMENTAL
Intervention: Real rTMS stimulation
Number of subjects: 48

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 48
Study: 17207174

Group type: EXPERIMENTAL
Intervention: Pimecrolimus cream 1%
Number of subjects: 40

Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 40
Study: 16368055

Group type: EXPERIMENTAL
Intervention: Etoricoxib 60 mg/day
Number of subjects: 446

Group type: COMPARATOR
Intervention: Diclofenac 150 mg/day
Number of subjects: 446
Study: 12174174

Group type: EXPERIMENTAL
Intervention: Mild cognitive impairment (MCI) diagnostic criteria based on neuropsychological tests and modified Clinical Dementia Rating (CDR) score of 0.5.
Number of subjects: 806

Group type: EXPERIMENTAL
Intervention: MCI diagnostic criteria
Number of subjects: 806
Study: 9549743

Group type: EXPERIMENTAL
Intervention: Granisetron (40 micrograms.kg-1)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Droperidol (50 micrograms.kg-1)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Metoclopramide (0.25 mg.kg-1)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 100
Study: 7618677

Group type: EXPERIMENTAL
Intervention: 20 mg droperidol added to 120 mg morphine in 60 ml saline
Number of subjects: 50
Study: 1618244

Group type: EXPERIMENTAL
Intervention: Pindolol 15 mg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Propranolol 80 mg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Cigarette smoking
Number of subjects: 6

Group type: COMPARATOR
Intervention: Sham smoking
Number of subjects: 6
Study: 6734073

Group type: EXPERIMENTAL
Intervention: Glycerol 92 mmol/l
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Glycerol 272 mmol/l
Number of subjects: 6

Group type: COMPARATOR
Intervention: Glucose 76 mmol/l
Number of subjects: 6

Group type: COMPARATOR
Intervention: Glucose 215 mmol/l
Number of subjects: 6
Study: 31404018

Group type: EXPERIMENTAL
Intervention: Imipenem 3 × 500 mg intravenously daily
Number of subjects: 98

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Imipenem
Number of subjects: 98
Study: 30289884

Group type: EXPERIMENTAL
Intervention: Brief video intervention (29-minute video with HIV-related health messages)
Number of subjects: 2023

Group type: COMPARATOR
Intervention: Control group (patients visiting clinics during the prior 10 months, N = 1,979)
Number of subjects: 2023
Study: 26972646

Group type: EXPERIMENTAL
Intervention: Cisplatin (30 mg/m²) and Irinotecan (50 mg/m²) on day 1, 8, 22, 29 during 45 Gy radiation therapy (RT), 1.8 Gy per day over 5 weeks.
Number of subjects: 86

Group type: COMPARATOR
Intervention: Cisplatin (30 mg/m²) and Paclitaxel (50 mg/m²) on day 1, 8, 15, 22, 29 with RT, followed by adjuvant cisplatin (75 mg/m²) and paclitaxel (175 mg/m²) day 1 every 21 days for 3 cycles.
Number of subjects: 86
Study: 25545025

Group type: EXPERIMENTAL
Intervention: Counselor-initiated condition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Self-paced condition
Number of subjects: 0

Group type: COMPARATOR
Intervention: Look AHEAD Intensive Lifestyle Intervention (ILI)
Number of subjects: 0
Study: 23992160

Group type: EXPERIMENTAL
Intervention: Nd‐YAG laser
Number of subjects: 15

Group type: COMPARATOR
Intervention: Pulsed dye laser (PDL)
Number of subjects: 15
Study: 20528705

Group type: EXPERIMENTAL
Intervention: Enhanced GP care plus MoodGYM (internet-based CBT)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Enhanced GP care
Number of subjects: 83
Study: 19138245

Group type: EXPERIMENTAL
Intervention: Neostigmine (100 microg)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 66
Study: 16601402

Group type: EXPERIMENTAL
Intervention: Modafinil (170-425 mg once daily)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study: 14551370

Group type: EXPERIMENTAL
Intervention: DIAPES HF800
Number of subjects: 10

Group type: COMPARATOR
Intervention: Polysulfone
Number of subjects: 10

Group type: COMPARATOR
Intervention: Polyamide
Number of subjects: 10
Study: 10977791

Group type: EXPERIMENTAL
Intervention: The Life Readiness Program (6-month rehabilitation program, n = 39)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Standard clinical management alone (control, n = 43)
Number of subjects: 82
Study: 9409567

Group type: EXPERIMENTAL
Intervention: Cyclic enteral nutrition (CYC)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Continuous enteral nutrition (CON)
Number of subjects: 57
Study: 8390559

Group type: EXPERIMENTAL
Intervention: Prophylactic ganciclovir (10 mg/kg/day)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Therapeutic ganciclovir (10 mg/kg/day)
Number of subjects: 65
Study: 2442558

Group type: EXPERIMENTAL
Intervention: Lisinopril (1.25‐10.0 mg) administered on days 1 and 3
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Lisinopril (oral and intravenous administration)
Number of subjects: 24
Study: 30077866

Group type: EXPERIMENTAL
Intervention: Mozart's Sonata for two pianos K.448
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Beethoven's Moonlight Sonata
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Heartbeat sound recordings (70 bpm)
Number of subjects: 80

Group type: COMPARATOR
Intervention: No music (control group)
Number of subjects: 80
Study: 27099270

Group type: EXPERIMENTAL
Intervention: 2-phenethyl isothiocyanate (PEITC) supplementation
Number of subjects: 82

Group type: COMPARATOR
Intervention: Control (smokers possessing both GSTM1 and GSTT1 genes)
Number of subjects: 82
Study: 25196930

Group type: EXPERIMENTAL
Intervention: 16 week individualized balance and strength home exercise program based on the Otago Exercise Program with additional exercises focused on improving turning ability.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual activities (Control group).
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 16 week individualized balance and strength home exercise program.
Number of subjects: 0
Study: 22503720

Group type: EXPERIMENTAL
Intervention: Xylazine (0.05 mg/kg BW, i.m.)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 24
Study: 20518174

Group type: EXPERIMENTAL
Intervention: Warming moxibustion (added on Guanyuan (CV 4), Qihai (CV 6), and Pishu (BL 20))
Number of subjects: 94

Group type: COMPARATOR
Intervention: Isotritinoin soft capsule (taken orally)
Number of subjects: 94

Group type: COMPARATOR
Intervention: No additional therapy (control group 2)
Number of subjects: 94
Study: 17309847

Group type: EXPERIMENTAL
Intervention: Celecoxib
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Coxibs
Number of subjects: 0
Study: 15685259

Group type: EXPERIMENTAL
Intervention: Tuli's grading system
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: ASIA scoring system
Number of subjects: 33
Study: 12008199

Group type: EXPERIMENTAL
Intervention: Postoperative radiotherapy to the chest wall and axilla (45 Gy in 15 fractions over 3 weeks)
Number of subjects: 76

Group type: COMPARATOR
Intervention: No further loco-regional treatment (watch policy)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Postoperative radiotherapy
Number of subjects: 76

Group type: COMPARATOR
Intervention: No radiotherapy
Number of subjects: 76
Study: 7819652

Group type: EXPERIMENTAL
Intervention: Branched-chain amino acids (BCAAs) in a carbohydrate solution
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo drink containing only carbohydrates
Number of subjects: 0
Study: 2891798

Group type: EXPERIMENTAL
Intervention: Postoperative RT plus chemotherapy with CAP (Cyclophosphamide, Adriamycin, and Cisplatin) for 6 months
Number of subjects: 172

Group type: COMPARATOR
Intervention: Postoperative RT alone
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Postoperative RT plus chemotherapy with CAP
Number of subjects: 172
Study: 31531733

Group type: EXPERIMENTAL
Intervention: Resistive vibration exercise (RVE) countermeasure
Number of subjects: 12

Group type: COMPARATOR
Intervention: Sedentary control (CON)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Tilt 80°
Number of subjects: 12
Study: 28473464

Group type: EXPERIMENTAL
Intervention: Protein ingestion during hyperinsulinemic-euglycemic clamp procedure (HECP)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Leucine ingestion during hyperinsulinemic-euglycemic clamp procedure (HECP)
Number of subjects: 30

Group type: COMPARATOR
Intervention: No protein or leucine ingestion during hyperinsulinemic-euglycemic clamp procedure (HECP)
Number of subjects: 30
Study: 25896566

Group type: EXPERIMENTAL
Intervention: Video Laryngoscopy (VL)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Direct Laryngoscopy (DL)
Number of subjects: 48
Study: 23138609

Group type: EXPERIMENTAL
Intervention: 300 mg clopidogrel loading dose
Number of subjects: 35

Group type: COMPARATOR
Intervention: 600 mg clopidogrel loading dose
Number of subjects: 35
Study: 21747288

Group type: EXPERIMENTAL
Intervention: Cluster Training (CT)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Traditional Training (TT)
Number of subjects: 18
Study: 19464878

Group type: EXPERIMENTAL
Intervention: Ropivacaine with sufentanil 0.5 microg/mL
Number of subjects: 53

Group type: COMPARATOR
Intervention: Levobupivacaine with sufentanil 0.5 microg/mL
Number of subjects: 53